October 9, 2026 – We are pleased to highlight an in-depth Q&A article published recently in Cell & Gene Therapy Insights featuring our Founder and CEO, Dr. Frank Borriello, in conversation with Commissioning Editor Abigail Pinchbeck.

Titled “Harnessing multiple immune pathways to drive antitumor activity,” the interview explores the scientific foundation, therapeutic rationale, and manufacturing philosophy driving Alloplex Biotherapeutics. Dr. Borriello shares how our proprietary ENLYST™ platform trains autologous immune cells into SUPLEXA™ cells: a non-engineered cellular therapy designed to engage coordinated, multi-mechanism immune responses against complex cancers.

Below are key takeaways from the conversation on how Alloplex is working to redefine cellular immunotherapy.

Rethinking cancer immunotherapy: The multi-pathway advantage

Traditional cell therapies often focus on a single receptor or pathway, which can yield limited or incremental activity against heterogeneous tumor microenvironments. In the interview, Dr. Borriello discusses the core thesis behind Alloplex: rather than targeting isolated pathways, why not activate the full, natural repertoire of the immune system simultaneously?

Our ENLYST platform utilizes artificial stimulator cells expressing a defined combination of key immunomodulatory proteins. By exposing a patient’s peripheral blood white blood cells to ENLYST ex vivo, we reawaken and train innate immune populations—including NK, NKT, and T cells—without changing their underlying DNA. The result is SUPLEXA: a potent, multi-functional cellular therapy capable of recognizing and destroying tumor cells across multiple recognition mechanisms.

Overcoming the bottlenecks of autologous cell therapy

Autologous cell therapies have historically faced criticism over batch-to-batch variability and high manufacturing costs. In his discussion with Cell & Gene Therapy Insights, Dr. Borriello outlines how Alloplex has directly addressed these industry challenges:

• No Genetic Engineering Required: By avoiding gene editing or viral vector delivery, SUPLEXA eliminates the safety concerns, genomic instability risks, and high material costs associated with genetic modification.
• Broad Applicability and Consistency: Despite starting from unique patient blood samples, our two-week ex vivo training protocol yields a consistent, highly activated cellular profile across diverse patient demographics and health profiles.
• Cost-Effective Scalability: By streamlining ex vivo processing, SUPLEXA can be manufactured at a fraction of the cost of conventional CAR-T therapies, removing major economic barriers for healthcare systems.

Unique pharmacodynamics and natural immunosurveillance

Addressing questions on durability and persistence, Dr. Borriello highlights an important biological distinction between non-engineered innate immune cells and CAR-T cells. Because SUPLEXA cells follow natural immunosurveillance pathways, they quickly exit bloodstream circulation to infiltrate tissues and solid tumor microenvironments.

Rather than relying on persistent cell counts in blood, efficacy is measured through long-term pharmacodynamic responses. In our first-in-human Phase 1 study, responding patients demonstrated durable clinical benefits without systemic toxicity, supporting the potential for robust single-agent activity.

A Vision for Decentralized, Accessible Care

Looking ahead, Dr. Borriello outlines our vision for the future of cell therapy delivery. Because SUPLEXA leverages a streamlined, non-engineered protocol, it opens the door to decentralized manufacturing models.

Our ultimate goal is to enable local community hospitals to process a simple patient blood draw into a personalized therapy within two weeks—allowing cancer patients to receive advanced cellular immunotherapy as an outpatient procedure close to home.

Note: ENLYST and SUPLEXA are trademarks or pending trademarks of Alloplex Biotherapeutics, Inc.

Read the full Q&A feature

To dive deeper into Dr. Borriello’s perspective on comparative cell therapy landscapes, ex vivo versus in vivo CAR-T approaches, and our ongoing clinical development priorities in hematologic and solid tumors, read the full open-access article in the journal.

Read the full article on Cell & Gene Therapy Insights

About Cell & Gene Therapy Insights:
Cell & Gene Therapy Insights is an online, open-access, peer-reviewed journal dedicated to advancing cell and gene therapy development and bridging academia and industry across the field. https://www.insights.bio/cell-and-gene-therapy-insights